Mammoth Biosciences的动态

Ready to use CRISPR for forward mutagenesis screening? Here's what you will need: * Start with a Cas9-expressing stable cell line * Have ready a CRISPR sgRNA Library for your pathway [or gene groups] * Perform your assay or phenotype screening So first things first - check our Cas9 Cell Line collections! ?? https://lnkd.in/gv_jPWCD #CRISPRscreening #ForwardGenetics #CRISPRCas9 #sgRNALibrary #Cas9StableCells #cellandgenetherapy #scientists #cellbiology #boitechnology#GenomeEditing #CRISPRKO #GeneEditingAssay

In today’s challenging and ever-evolving landscape of clinical trials, especially in the complex field of cell and gene therapy (CGT), the importance of focusing on the finer details cannot be overstated.?Emmes AI-enabled technology allows you to go beyond traditional solutions by leveraging insights from past experiences, correcting previous errors, and accelerating the entire trial process. In a world where speed and precision are critical, it’s time to be agile, create synergies, and advance science. ? We are here to offer the tools you need to make that happen. Read below to learn more. #ClinicalTrials #CellAndGeneTherapy #Biotech #ClinicalResearch #CRO #Innovation

Breaking News: BGF 2025 Panel Topics Revealed! ? Get ready for three dynamic panel discussions that tackle the biggest challenges and opportunities in biotech: 1?? 2025 Cell and Gene Therapy Market 2?? Conquering CGT's challenges in biomanufacturing and supply chain management 3?? How new therapeutic and technology platforms are shaping the future of CGT ?? Register now: https://bit.ly/48sG9l4 ?? Gain cutting-edge perspectives from industry leaders and experts in these can't-miss sessions! #GenScript #CellAndGeneTherapy #GenScriptBiotechGlobalForum2025 #Networking #GeneTherapy #LifeScience #Biotech #BiotechLeaders

Clinical-scale non-viral gene edited #CARNKcells for #celltherapy Despite the promise of #NaturalKiller (NK) cells for #allogeneiccelltherapy, there are challenges associated with clinical-scale #geneediting and hurdles such as the upregulation of NK-inhibitory ligands within the tumor microenvironment. Next month, Thermo Fisher Scientific’s Namritha Ravinder (Director if R&D) and Wisconsin Institute for Discovery’s Krishanu Saha (Associate Professor) will present novel #nonviralcelltherapy processing workflows and discuss how CRISPR-Cas9 can be harnessed to perform no-nviral insertion of #CARgenes within #NKcells Register for this #webinar below:

Want a first look at our innovative platform for unlocking patient access to life-saving cell and gene therapies? Heading to ISCT, International Society for Cell & Gene Therapy's conference in Vancouver? Then book a live demo with the Ori Biotech team here - https://lnkd.in/eANBmhCP Not lucky enough to be joining, but still want to check it out? Sneaky peek below ??

Clinical-scale non-viral gene edited #CARNKcells for #celltherapy Despite the promise of #NaturalKiller (NK) cells for #allogeneiccelltherapy, there are challenges associated with clinical-scale #geneediting and hurdles such as the upregulation of NK-inhibitory ligands within the tumor microenvironment. Next month, Thermo Fisher Scientific’s Namritha Ravinder (Director if R&D) and Wisconsin Institute for Discovery’s Krishanu Saha (Associate Professor) will present novel #nonviralcelltherapy processing workflows and discuss how CRISPR-Cas9 can be harnessed to perform no-nviral insertion of #CARgenes within #NKcells Register for this #webinar below:

Fanzor2, a eukaryotic CRISPR-Cas homolog, characterized using advanced cryo-electron microscopy. This breakthrough, led by Elizabeth Kellogg and team at St. Jude Children's Research Hospital, could revolutionize gene editing by providing new insights into the mechanisms of CRISPR systems in eukaryotes. Really excited about this as it will be adding to the toolbox we may use for therapeutic applications. #CRISPRCas9 #GeneEditing #structuralbiology

Cell and Gene Therapy (CGT) manufacturing is complex, with success relying on efficiency, quality, and cost-effectiveness. ??Combining Design of Experiments (DoE)?with Virica’s VSE? cell enhancers, High-Throughput Virology and Culture Biosciences scalable cloud-connected bioreactors: ? Rapidly optimizes viral vector production to accelerate your processes. ? Boosts viral vector yield and quality ? Unlocks robust scaling efficiency Attending ATW 2025 next week? Be sure to catch Azra Benson from Virica and Jean-Marc Guedon from Culture Biosciences to learn how Virica’s?Viral Sensitizer (VSE??) and Culture Biosciences cloud-based bioreactors can accelerate your CGT production! ?? Booth #214 ?? Innovation Zone on Tuesday 21st 2:30 – 3:00 pm CST! #innovation #biomanufacturing #ATW2025 #DoE

Teddy JéGU, our Director of Research, will be speaking at the Next Generation Therapy Vector Summit, being held in Boston from June 12-14. ? This is the only industry-focused event covering the latest advances and innovations in vector development for gene therapies. ? Teddy will be discussing EG 427’s unique technology, focusing on three main points: the characteristics of our non-replicative HSV-1 vector platform; its applications in the peripheral nervous system, such as EG 110A in neurogenic detrusor overactivity (NDO); and its applications in the central nervous system. The talk will take place on June 14 at 2:15pm. ? Our solution provides, potential for long-term expression and high safety profile. The high neurotropism and natural retrograde transport of our vectors make them targeted DNA delivery cargos to the nervous system. ? Please get in touch if you’d like to schedule a meeting at the event. https://lnkd.in/ezpHs5EQ ? #genetherapy?#biotech #drugdevelopment

As the future of healthcare advances through cell and gene therapies, cryopreservation is vital in ensuring that life-saving treatments reach patients without compromise. Imagine a future where therapies can be ‘frozen in time’ to align with the demands of personalised medicine, global access, and sustainable logistics. At Air Products, our cryogenic storage and liquid nitrogen solutions are crafted to support this vision, making it possible to store, transport, and deliver therapies when and where they’re needed. Let’s rethink what’s possible in cryopreservation to help shape the path forward. Check out this interesting discussion by the The Medicine Maker around the trends, challenges, and possibilities of cryopreservation for cell and gene therapies and the future: https://lnkd.in/e7DMUrZK #Cryopreservation #CellAndGene #AdvancedTherapies